Symbols / ELAN Stock $22.75 +1.61% Elanco Animal Health Incorporated

Healthcare • Drug Manufacturers - Specialty & Generic • United States • NYQ
ELAN (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
CEO Mr. Jeffrey N. Simmons
Exch · Country NYQ · United States
Market Cap 11.36B
Enterprise Value 15.21B
Income -232.00M
Sales 4.71B
FCF (ttm) 559.75M
Book/sh 13.17
Cash/sh 1.10
Employees 9,400
Insider 10d —
IPO Sep 20, 2018
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E 19.47
PEG 3.83
P/S 2.41
P/B 1.73
P/C —
EV/EBITDA 16.75
EV/Sales 3.23
Quick Ratio 1.00
Current Ratio 2.17
Debt/Eq 67.89
LT Debt/Eq —
EPS (ttm) -0.47
EPS next Y 1.17
EPS Growth —
Revenue Growth 12.20%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-06
Earnings (prior) 2026-02-24
ROA 1.25%
ROE -3.67%
ROIC —
Gross Margin 55.00%
Oper. Margin 2.27%
Profit Margin -4.92%
Shs Outstand 499.38M
Shs Float 492.68M
Insider Own 1.19%
Instit Own 109.85%
Short Float 7.82%
Short Ratio 4.11
Short Interest 24.56M
52W High 27.72
vs 52W High -17.93%
52W Low 9.32
vs 52W Low 144.10%
Beta 1.88
Impl. Vol. 58.98%
Rel Volume 0.64
Avg Volume 4.83M
Volume 3.08M
Target (mean) $28.79
Tgt Median $30.00
Tgt Low $20.00
Tgt High $32.00
# Analysts 14
Recom Strong_buy
Prev Close $22.39
Price $22.75
Change 1.61%
About

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. It also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, the company offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, it offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and Tru Family trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. The company sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Indianapolis, Indiana.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$28.79
Mean price target
2. Current target
$22.75
Latest analyst target
3. DCF / Fair value
$20.18
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$22.75
Low
$20.00
High
$32.00
Mean
$28.79

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-15 init Citigroup — → Buy $30
2026-02-25 main Morgan Stanley Equal-Weight → Equal-Weight $24
2026-02-25 main Keybanc Overweight → Overweight $29
2026-02-24 main Leerink Partners Outperform → Outperform $30
2026-02-19 main JP Morgan Overweight → Overweight $28
2026-01-22 up Piper Sandler Neutral → Overweight $30
2025-12-18 main Morgan Stanley Equal-Weight → Equal-Weight $22
2025-12-09 init Barclays — → Overweight $30
2025-11-21 init Keybanc — → Overweight $27
2025-11-06 main UBS Buy → Buy $27
2025-10-20 main UBS Buy → Buy $25
2025-10-07 up JP Morgan Neutral → Overweight $24
2025-09-24 main Stifel Buy → Buy $23
2025-08-11 main Piper Sandler Neutral → Neutral $18
2025-08-08 main UBS Buy → Buy $19
2025-07-23 main UBS Buy → Buy $18
2025-07-17 up Leerink Partners Market Perform → Outperform $18
2025-07-02 main Stifel Buy → Buy $17
2025-06-26 up William Blair Market Perform → Outperform —
2025-05-19 main Stifel Buy → Buy $16
News
RSS: Latest ELAN news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-01 DE BRABANDER ELLEN Officer — 40,985 $0.00 $0
2026-02-27 SIMMONS JEFFREY N. Chief Executive Officer — 516,360 $0.00 $0
2026-02-27 VANHIMBERGEN ROBERT M Chief Financial Officer — 23,675 $0.00 $0
2026-02-27 CABRAL RAMIRO MARTIN Officer — 80,887 $0.00 $0
2026-02-27 KINARD DAVID S Officer — 42,557 $0.00 $0
2026-02-27 MEER JAMES M Officer — 14,805 $0.00 $0
2026-02-27 BETTINGTON TIMOTHY J Officer — 55,792 $0.00 $0
2026-02-27 CORREIA DE SIMAS JOSE MANUEL Officer — 32,871 $0.00 $0
2026-02-27 DE BRABANDER ELLEN Officer — 92,924 $0.00 $0
2026-02-27 MODI RAJEEV A Officer — 55,895 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
4,715.00
+6.22%
4,439.00
+0.50%
4,417.00
+0.14%
4,411.00
Operating Revenue
4,715.00
+6.22%
4,439.00
+0.50%
4,417.00
+0.14%
4,411.00
Cost Of Revenue
2,122.00
+5.94%
2,003.00
+3.73%
1,931.00
+0.94%
1,913.00
Reconciled Cost Of Revenue
1,985.00
+6.26%
1,868.00
+4.65%
1,785.00
+1.48%
1,759.00
Gross Profit
2,593.00
+6.44%
2,436.00
-2.01%
2,486.00
-0.48%
2,498.00
Operating Expense
2,341.00
+7.14%
2,185.00
+1.16%
2,160.00
+2.18%
2,114.00
Research And Development
368.00
+6.98%
344.00
+5.20%
327.00
+1.87%
321.00
Selling General And Administration
1,430.00
+8.83%
1,314.00
+2.26%
1,285.00
+1.58%
1,265.00
Total Expenses
4,463.00
+6.57%
4,188.00
+2.37%
4,091.00
+1.59%
4,027.00
Operating Income
252.00
+0.40%
251.00
-23.01%
326.00
-15.10%
384.00
EBITDA
676.00
-51.19%
1,385.00
+718.30%
-224.00
-126.32%
851.00
Normalized EBITDA
913.00
+2.01%
895.00
-5.29%
945.00
-8.61%
1,034.00
Reconciled Depreciation
680.00
+2.72%
662.00
-4.61%
694.00
+1.76%
682.00
EBIT
-4.00
-100.55%
723.00
+178.76%
-918.00
-643.20%
169.00
Total Unusual Items
-237.00
-148.37%
490.00
+141.92%
-1,169.00
-538.80%
-183.00
Total Unusual Items Excluding Goodwill
-237.00
-148.37%
490.00
+141.92%
-1,169.00
-538.80%
-183.00
Special Income Charges
-237.00
-148.37%
490.00
+141.92%
-1,169.00
-538.80%
-183.00
Other Special Charges
8.00
+14.29%
7.00
+250.00%
2.00
-50.00%
4.00
Impairment Of Capital Assets
71.00
-12.35%
81.00
-92.46%
1,074.00
+1225.93%
81.00
Restructuring And Mergern Acquisition
119.00
+91.94%
62.00
-33.33%
93.00
-5.10%
98.00
Write Off
39.00
—
—
—
Net Income
-232.00
-168.64%
338.00
+127.46%
-1,231.00
-1478.21%
-78.00
Pretax Income
-224.00
-145.90%
488.00
+140.84%
-1,195.00
-1559.72%
-72.00
Net Non Operating Interest Income Expense
-220.00
+6.38%
-235.00
+15.16%
-277.00
-14.94%
-241.00
Interest Expense Non Operating
220.00
-6.38%
235.00
-15.16%
277.00
+14.94%
241.00
Net Interest Income
-220.00
+6.38%
-235.00
+15.16%
-277.00
-14.94%
-241.00
Interest Expense
220.00
-6.38%
235.00
-15.16%
277.00
+14.94%
241.00
Other Income Expense
-256.00
-154.24%
472.00
+137.94%
-1,244.00
-478.60%
-215.00
Other Non Operating Income Expenses
-19.00
-5.56%
-18.00
+76.00%
-75.00
-134.38%
-32.00
Gain On Sale Of Business
0.00
-100.00%
640.00
0.00
0.00
Tax Provision
8.00
-94.67%
150.00
+316.67%
36.00
+500.00%
6.00
Tax Rate For Calcs
0.00
-31.60%
0.00
+46.19%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
-49.77
-133.09%
150.43
+161.28%
-245.49
-538.80%
-38.43
Net Income Including Noncontrolling Interests
-232.00
-168.64%
338.00
+127.46%
-1,231.00
-1478.21%
-78.00
Net Income From Continuing Operation Net Minority Interest
-232.00
-168.64%
338.00
+127.46%
-1,231.00
-1478.21%
-78.00
Net Income From Continuing And Discontinued Operation
-232.00
-168.64%
338.00
+127.46%
-1,231.00
-1478.21%
-78.00
Net Income Continuous Operations
-232.00
-168.64%
338.00
+127.46%
-1,231.00
-1478.21%
-78.00
Normalized Income
-44.77
-2751.59%
-1.57
+99.49%
-307.49
-561.90%
66.57
Net Income Common Stockholders
-232.00
-168.64%
338.00
+127.46%
-1,231.00
-1478.21%
-78.00
Diluted EPS
-0.47
-169.12%
0.68
+127.20%
-2.50
-1566.67%
-0.15
Basic EPS
-0.47
-169.12%
0.68
+127.20%
-2.50
-1566.67%
-0.15
Basic Average Shares
496.40
+0.49%
494.00
+0.35%
492.30
+0.82%
488.30
Diluted Average Shares
496.40
-0.18%
497.30
+1.02%
492.30
+0.82%
488.30
Diluted NI Availto Com Stockholders
-232.00
-168.64%
338.00
+127.46%
-1,231.00
-1478.21%
-78.00
Amortization
543.00
+3.04%
527.00
-3.83%
548.00
+3.79%
528.00
Amortization Of Intangibles Income Statement
543.00
+3.04%
527.00
-3.83%
548.00
+3.79%
528.00
Depreciation Amortization Depletion Income Statement
543.00
+3.04%
527.00
-3.83%
548.00
+3.79%
528.00
Depreciation And Amortization In Income Statement
543.00
+3.04%
527.00
-3.83%
548.00
+3.79%
528.00
Gain On Sale Of PPE
—
—
—
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
13,358.00
+5.90%
12,614.00
-12.17%
14,362.00
-7.29%
15,491.00
Current Assets
3,458.00
+7.56%
3,215.00
-5.64%
3,407.00
+3.90%
3,279.00
Cash Cash Equivalents And Short Term Investments
545.00
+16.45%
468.00
+32.95%
352.00
+2.03%
345.00
Cash And Cash Equivalents
545.00
+16.45%
468.00
+32.95%
352.00
+2.03%
345.00
Receivables
940.00
+6.09%
886.00
-12.28%
1,010.00
+0.80%
1,002.00
Accounts Receivable
873.00
+8.45%
805.00
-4.39%
842.00
+5.65%
797.00
Gross Accounts Receivable
890.00
+8.80%
818.00
-4.88%
860.00
+6.17%
810.00
Allowance For Doubtful Accounts Receivable
-17.00
-30.77%
-13.00
+27.78%
-18.00
-38.46%
-13.00
Other Receivables
67.00
-17.28%
81.00
-51.79%
168.00
-18.05%
205.00
Inventory
1,737.00
+10.36%
1,574.00
-9.28%
1,735.00
+12.81%
1,538.00
Raw Materials
104.00
+6.12%
98.00
-23.44%
128.00
-1.54%
130.00
Work In Process
837.00
+6.90%
783.00
-3.81%
814.00
+19.18%
683.00
Finished Goods
871.00
+15.52%
754.00
-12.02%
857.00
+9.45%
783.00
Prepaid Assets
—
—
—
—
Restricted Cash
—
—
—
—
Other Current Assets
236.00
-17.77%
287.00
-7.42%
310.00
-21.32%
394.00
Total Non Current Assets
9,900.00
+5.33%
9,399.00
-14.20%
10,955.00
-10.29%
12,212.00
Net PPE
1,409.00
+41.89%
993.00
-3.22%
1,026.00
+2.70%
999.00
Gross PPE
2,361.00
+27.55%
1,851.00
+0.54%
1,841.00
+6.91%
1,722.00
Accumulated Depreciation
-952.00
-10.96%
-858.00
-5.28%
-815.00
-12.72%
-723.00
Properties
0.00
0.00
0.00
0.00
Land And Improvements
66.00
+65.00%
40.00
+0.00%
40.00
+0.00%
40.00
Buildings And Improvements
698.00
+16.33%
600.00
-4.76%
630.00
+9.00%
578.00
Machinery Furniture Equipment
—
—
—
941.00
Construction In Progress
268.00
+21.27%
221.00
+18.82%
186.00
+14.11%
163.00
Other Properties
1,329.00
+34.24%
990.00
+0.51%
985.00
+4.68%
941.00
Goodwill And Other Intangible Assets
8,187.00
+1.14%
8,095.00
-15.57%
9,588.00
-11.51%
10,835.00
Goodwill
4,779.00
+8.27%
4,414.00
-13.35%
5,094.00
-15.00%
5,993.00
Other Intangible Assets
3,408.00
-7.42%
3,681.00
-18.09%
4,494.00
-7.19%
4,842.00
Other Non Current Assets
304.00
-2.25%
311.00
-8.80%
341.00
-9.79%
378.00
Total Liabilities Net Minority Interest
6,811.00
+4.50%
6,518.00
-19.92%
8,139.00
-0.77%
8,202.00
Current Liabilities
1,597.00
+21.44%
1,315.00
+5.96%
1,241.00
-27.09%
1,702.00
Payables And Accrued Expenses
368.00
+24.32%
296.00
+9.63%
270.00
-30.77%
390.00
Payables
368.00
+24.32%
296.00
+9.63%
270.00
-30.77%
390.00
Accounts Payable
368.00
+24.32%
296.00
+9.63%
270.00
-30.77%
390.00
Employee Benefits
158.00
-9.71%
175.00
-4.89%
184.00
+14.29%
161.00
Pensionand Other Post Retirement Benefit Plans Current
206.00
+16.38%
177.00
+12.74%
157.00
+7.53%
146.00
Current Debt And Capital Lease Obligation
74.00
+68.18%
44.00
+15.79%
38.00
-90.21%
388.00
Current Debt
74.00
+68.18%
44.00
+15.79%
38.00
-90.21%
388.00
Current Deferred Liabilities
416.00
+25.30%
332.00
-9.54%
367.00
+13.27%
324.00
Other Current Liabilities
533.00
+14.38%
466.00
+13.94%
409.00
-9.91%
454.00
Total Non Current Liabilities Net Minority Interest
5,214.00
+0.21%
5,203.00
-24.57%
6,898.00
+6.12%
6,500.00
Liabilities Heldfor Sale Non Current
304.00
0.00
—
—
Long Term Debt And Capital Lease Obligation
3,943.00
-7.81%
4,277.00
-25.44%
5,736.00
+5.29%
5,448.00
Long Term Debt
3,943.00
-7.81%
4,277.00
-25.44%
5,736.00
+5.29%
5,448.00
Non Current Pension And Other Postretirement Benefit Plans
158.00
-9.71%
175.00
-4.89%
184.00
+14.29%
161.00
Non Current Deferred Liabilities
382.00
-14.92%
449.00
-20.81%
567.00
-14.35%
662.00
Non Current Deferred Taxes Liabilities
382.00
-14.92%
449.00
-20.81%
567.00
-14.35%
662.00
Other Non Current Liabilities
427.00
+41.39%
302.00
-26.52%
411.00
+79.48%
229.00
Stockholders Equity
6,547.00
+7.40%
6,096.00
-2.04%
6,223.00
-14.62%
7,289.00
Common Stock Equity
6,547.00
+7.40%
6,096.00
-2.04%
6,223.00
-14.62%
7,289.00
Capital Stock
0.00
0.00
0.00
0.00
Common Stock
0.00
0.00
0.00
0.00
Preferred Stock
0.00
0.00
—
0.00
Share Issued
496.98
+0.51%
494.45
+0.32%
492.85
+3.92%
474.24
Ordinary Shares Number
496.98
+0.51%
494.45
+0.32%
492.85
+3.92%
474.24
Additional Paid In Capital
8,870.00
+0.60%
8,817.00
+0.46%
8,777.00
+0.45%
8,738.00
Retained Earnings
-2,182.00
-11.90%
-1,950.00
+14.77%
-2,288.00
-116.46%
-1,057.00
Gains Losses Not Affecting Retained Earnings
-141.00
+81.71%
-771.00
-189.85%
-266.00
+32.14%
-392.00
Other Equity Adjustments
-141.00
+81.71%
-771.00
-189.85%
-266.00
+32.14%
-392.00
Total Equity Gross Minority Interest
6,547.00
+7.40%
6,096.00
-2.04%
6,223.00
-14.62%
7,289.00
Total Capitalization
10,490.00
+1.13%
10,373.00
-13.26%
11,959.00
-6.11%
12,737.00
Working Capital
1,861.00
-2.05%
1,900.00
-12.28%
2,166.00
+37.35%
1,577.00
Invested Capital
10,564.00
+1.41%
10,417.00
-13.17%
11,997.00
-8.59%
13,125.00
Total Debt
4,017.00
-7.04%
4,321.00
-25.16%
5,774.00
-1.06%
5,836.00
Net Debt
3,472.00
-9.89%
3,853.00
-28.94%
5,422.00
-1.26%
5,491.00
Net Tangible Assets
-1,640.00
+17.96%
-1,999.00
+40.59%
-3,365.00
+5.10%
-3,546.00
Tangible Book Value
-1,640.00
+17.96%
-1,999.00
+40.59%
-3,365.00
+5.10%
-3,546.00
Inventories Adjustments Allowances
-75.00
-22.95%
-61.00
+4.69%
-64.00
-10.34%
-58.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
560.00
+3.51%
541.00
+99.63%
271.00
-40.04%
452.00
Cash Flow From Continuing Operating Activities
560.00
+3.51%
541.00
+99.63%
271.00
-40.04%
452.00
Net Income From Continuing Operations
-232.00
-168.64%
338.00
+127.46%
-1,231.00
-1478.21%
-78.00
Depreciation Amortization Depletion
680.00
+2.72%
662.00
-4.61%
694.00
+1.76%
682.00
Depreciation And Amortization
680.00
+2.72%
662.00
-4.61%
694.00
+1.76%
682.00
Other Non Cash Items
8.00
+0.00%
8.00
-88.24%
68.00
-67.15%
207.00
Stock Based Compensation
68.00
+23.64%
55.00
+19.57%
46.00
-22.03%
59.00
Asset Impairment Charge
71.00
-12.35%
81.00
-92.46%
1,074.00
+1225.93%
81.00
Deferred Tax
-134.00
-19.64%
-112.00
-40.00%
-80.00
-40.35%
-57.00
Deferred Income Tax
-134.00
-19.64%
-112.00
-40.00%
-80.00
-40.35%
-57.00
Operating Gains Losses
—
-640.00
—
20.00
Change In Working Capital
99.00
-33.56%
149.00
+149.67%
-300.00
+35.06%
-462.00
Change In Receivables
-12.00
-200.00%
12.00
+130.00%
-40.00
-385.71%
14.00
Change In Inventory
-57.00
-229.55%
44.00
+127.50%
-160.00
+40.52%
-269.00
Change In Payables And Accrued Expense
147.00
+79.27%
82.00
+187.23%
-94.00
+4.08%
-98.00
Change In Payable
147.00
+79.27%
82.00
+187.23%
-94.00
+4.08%
-98.00
Change In Account Payable
147.00
+79.27%
82.00
+187.23%
-94.00
+4.08%
-98.00
Change In Other Working Capital
—
—
—
—
Change In Other Current Assets
21.00
+90.91%
11.00
+283.33%
-6.00
+94.50%
-109.00
Investing Cash Flow
-279.00
-124.09%
1,158.00
+785.21%
-169.00
+5.59%
-179.00
Cash Flow From Continuing Investing Activities
-279.00
-124.09%
1,158.00
+785.21%
-169.00
+5.59%
-179.00
Net PPE Purchase And Sale
-276.00
-87.76%
-147.00
-5.00%
-140.00
+18.13%
-171.00
Purchase Of PPE
-276.00
-87.76%
-147.00
-5.00%
-140.00
+18.13%
-171.00
Sale Of PPE
—
—
—
0.00
Capital Expenditure
-276.00
-87.76%
-147.00
-5.00%
-140.00
+23.91%
-184.00
Net Business Purchase And Sale
9.00
-99.32%
1,319.00
+7042.11%
-19.00
-246.15%
13.00
Purchase Of Business
0.00
+100.00%
-41.00
-115.79%
-19.00
0.00
Gain Loss On Sale Of Business
0.00
+100.00%
-640.00
0.00
0.00
Net Intangibles Purchase And Sale
—
-14.00
+0.00%
-14.00
-7.69%
-13.00
Purchase Of Intangibles
—
-14.00
+0.00%
-14.00
-7.69%
-13.00
Net Other Investing Changes
-12.00
+14.29%
-14.00
-40.00%
-10.00
-25.00%
-8.00
Financing Cash Flow
-275.00
+81.57%
-1,492.00
-1697.59%
-83.00
+84.88%
-549.00
Cash Flow From Continuing Financing Activities
-275.00
+81.57%
-1,492.00
-1697.59%
-83.00
+84.88%
-549.00
Net Issuance Payments Of Debt
-563.00
+61.83%
-1,475.00
-1815.58%
-77.00
+84.66%
-502.00
Issuance Of Debt
2,356.00
+313.33%
570.00
-5.00%
600.00
-39.27%
988.00
Repayment Of Debt
-2,919.00
-42.74%
-2,045.00
-202.07%
-677.00
+54.56%
-1,490.00
Long Term Debt Issuance
2,356.00
+313.33%
570.00
-5.00%
600.00
-39.27%
988.00
Long Term Debt Payments
-2,919.00
-42.74%
-2,045.00
-202.07%
-677.00
+54.56%
-1,490.00
Net Long Term Debt Issuance
-563.00
+61.83%
-1,475.00
-1815.58%
-77.00
+84.66%
-502.00
Short Term Debt Issuance
—
—
—
563.00
Short Term Debt Payments
—
—
—
-813.00
Net Short Term Debt Issuance
—
—
—
-250.00
Net Common Stock Issuance
—
—
—
0.00
Net Other Financing Charges
288.00
+1794.12%
-17.00
-183.33%
-6.00
+87.23%
-47.00
Changes In Cash
6.00
-97.10%
207.00
+989.47%
19.00
+106.88%
-276.00
Effect Of Exchange Rate Changes
71.00
+178.02%
-91.00
-658.33%
-12.00
+29.41%
-17.00
Beginning Cash Position
468.00
+32.95%
352.00
+2.03%
345.00
-45.92%
638.00
End Cash Position
545.00
+16.45%
468.00
+32.95%
352.00
+2.03%
345.00
Free Cash Flow
284.00
-27.92%
394.00
+200.76%
131.00
-51.12%
268.00
Common Stock Issuance
—
—
—
0.00
Issuance Of Capital Stock
—
—
—
0.00
Sale Of Business
9.00
-99.34%
1,360.00
0.00
-100.00%
13.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category